Healthy Aging Supplement Fails in Large PD Trial

27 Oct 2026 0 comments

Despite promising results in smaller trials, nicotinamide riboside fails to slow the progression of early Parkinson’s disease in a phase 3 study.
Medscape Medical News

Source: Medscape Neurology Published 27 Oct 2026 Imported 27 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment